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Abstract
Background: We have previously reported that rheumatoid arthritis patients, who adopted a
modified Cretan Mediterranean diet, obtained a reduction in disease activity and an improvement
in physical function and vitality. This shift in diet is likely to result in an altered intake of fatty acids.
Therefore, the objective of the present study was to examine the dietary intake of fatty acids, as
well as the fatty acid profile in serum phospholipids, during the dietary intervention study presented
earlier.
Results: From baseline to the end of the study, changes in the reported consumption of various
food groups were observed in the Mediterranean diet group. The change in diet resulted in a
number of differences between the Mediterranean diet group and the control diet group regarding
the fatty acid intake. For instance, a lower ratio of n-6 to n-3 fatty acids was observed in the
Mediterranean diet group, both assessed by diet history interviews (dietary intake) and measured
in serum phospholipids. Moreover, the patients in the Mediterranean diet group that showed a
moderate or better clinical improvement during the study (diet responders), had a higher reported
intake of n-3 fatty acids and a lower ratio of n-6 to n-3 fatty acids compared to the patients with
minor or no improvement. Also the fatty acid profile in serum phospholipids differed in part
between the diet responders and the diet non-responders.
Conclusion: The changes in the fatty acid profile, indicated both by dietary assessments and
through fatty acids in s-phospholipids may, at least in part, explain the beneficial effects of the
Cretan Mediterranean diet that we have presented earlier.
Background
We have previously reported that a shift to a modified
Cretan Mediterranean diet decreased the disease activity
and improved the physical function and vitality of Swed-
ish rheumatoid arthritis (RA) patients [1]. Among the
characteristics of the experimental diet used in this study,
was a relatively high consumption of fish, olive oil and
canola (rapeseed) oil, as well as a low intake of other fats
and of red meat. A change from a typical Swedish diet to
a Cretan Mediterranean diet is likely to result in a changed
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intake of fatty acids, for example an increased intake of n-
3 fatty acids. The impact of dietary fatty acids on rheuma-
toid inflammation has been investigated in a number of
in-vitro and animal studies, as well as in randomized, pla-
cebo-controlled trials [2]. The fatty acids most thoroughly
studied in relation to RA, are the n-3 fatty acids eicosapen-
taenoic acid (EPA; 20:5n-3) and docosahexaenoic acid
(DHA; 22:6n-3). At least thirteen randomized controlled
trials, ranging from 12 to 52 weeks, have shown that sup-
plementation with fish oil (which contains EPA and
DHA) resulted in beneficial effects on RA symptoms [3,4].
The most commonly observed benefit is a decreased
number of tender joints [5], but improvements in morn-
ing stiffness, number of swollen joints, pain index, physi-
cians global assessment and grip strength have also been
reported [4]. In addition, a meta-analysis, as well as a
mega-analysis (in which the original data sets were ana-
lysed), confirmed the efficacy of fish oils in reducing RA
symptoms [6]. However, only the reduction in the tender
joint count and in morning stiffness was shown to be sta-
tistically significant using these approaches.
In supplementation studies, olive oil has sometimes been
used as a placebo oil. In some of these studies improve-
ments were reported also in the group of RA patients
treated with olive oil [7-9]. The exact mechanism for this
effect has been uncertain. However, in a recent study, a
compound in extra-virgin olive oil, called oleocanthal,
was shown to inhibit the activity of cyclooxygenase
enzymes [10].
The relationship between n-3 fatty acids/fish intake, olive
oil and RA, has also been observed in case control studies.
In these studies a high consumption of fish [11] and olive
oil [12,13] was associated with decreased risk of develop-
ing RA.
In view of the results from earlier studies, the beneficial
effects observed in the randomized controlled trial in
which the Cretan Mediterranean diet was tested [1], may
be caused by an increse in n-3 fatty acids in relation to n-
6 fatty acids and/or an increased intake of olive oil. The
aim of the present study was to examine the consumption
of food items with relevance to the fat intake, the dietary
intake of fatty acids, as well as the fatty acid profile in
serum phospholipids, in the subjects participating in this
study.
Results
Reported dietary intake
To estimate the reported consumption of foods with rele-
vance to the fatty acid intake, a self-administrated ques-
tionnaire was used. At baseline the Cretan Mediterranean
diet (MD) group (n = 26) and the control diet (CD) group
(n = 25) reported a similar intake frequency of all the food
groups investigated (Table 1). By the end of the study the
MD group had decreased their intake of several food
groups such as meat, processed meat (including cured
meat, sausage, pâté or the like), sweets and high fat dairy
products, while the intake of fish, shellfish, poultry and
cheese with less than 17% fat, had increased compared to
Table 1: Comparison of reported food consumption frequencies (servings per month) between the Mediterranean Diet (MD) group 
and the Control Diet (CD) group.
MD group (n = 26) CD group (n = 25) P-value*
Time (weeks after dietary shift) Time (weeks after start of study)
0 3 12 0 3 12
Fish 6 (6-6) 16 (6–16) 16 (16-16)§ 6 (2–6) 6 (6–16) 6 (2–6) <0.001
Shellfish 2 (0–2) 2 (0–6) 4 (2–6)‡ 2 (0–2) 2 (0–2) 2 (0–2) <0.001
Meat, minced meat or offal from pig, cattle or sheep 16 (6–16) 0 (0-0) 0 (0-0)§ 16 (6–16) 6 (6–16) 6 (6–16)† <0.001
Poultry 2 (2–6) 16 (6–16) 11 (6–16)§ 2 (2–6) 2 (2–6) 2 (2–6) <0.001
Processed meat¶(not on bread) 6 (2–6) 0 (0-0) 0 (0-0)§ 6 (2–6) 6 (2–6) 2 (2–6) <0.001
Processed meat¶on bread 11 (6–26) 0 (0-0) 0 (0-0)§ 16 (2–16) 6 (4–16) 6 (2–16) <0.001
Cheese with more than 17% fat 16 (14–26) 0 (0-0) 0 (0-0)§ 26 (11–70) 16 (4–26) 16 (4–26) 0.002
Cheese with less than 17% fat 6 (0–9) 16 (0–26) 16 (6–26)‡ 0 (0–4) 0 (0–6) 0 (0–11) 0.005
Dairy products with 27% fat or more 2 (0–6) 0 (0-0) 0 (0-0)‡ 2 (0–6) 2 (0–6) 6 (2–6) <0.001
Dairy products with 10–15% fat 2 (0–6) 0 (0-0) 0 (0–2)‡ 2 (0–6) 0 (0–6) 0 (0–6) 0.013
Ice cream 2 (0–6) 0 (0–0.5) 0 (0–2)‡ 2 (0–4) 2 (0–2) 2 (0–2) 0.015
Sweets (including chocolate) 6 (2–16) 0 (0–2) 0 (0–2)§ 6 (1–6) 6 (0–6) 6 (2–6) <0.001
Buns, cookies or cakes 6 (5–16) 0 (0–2) 0 (0–2)§ 6 (2–16) 6 (2–16) 6 (2–16) <0.001
Nuts 0 (0–2) 0 (0–2) 0 (0–3) 0 (0–2) 0 (0–2) 0 (0–2) 0.704
Seeds 0 (0-0) 0 (0–2) 0 (0–2) 0 (0-0) 0 (0-0) 0 (0-0) 0.016
Data are presented as medians (25th–75th percentiles). *The p-values refer to differences between the MD- and the CD group concerning the 
change from baseline to week 12. Differences between the groups were analyzed with the Mann-Whitney U test. Statistically significant change from 
baseline to week 12: †p < 0.05; ‡p < 0.01; §p < 0.001. Within-group differences in week 12 compared to baseline were evaluated by the Wilcoxon 
signed ranks test. ¶Including cured meat, sausage, pâté or the like.Nutrition & Metabolism 2005, 2:26 http://www.nutritionandmetabolism.com/content/2/1/26
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baseline. The CD group also decreased their intake of
meat, from baseline to the end of the study, but apart
from that, no differences were seen in that group regard-
ing the intake frequencies of foods with relevance to the
fatty acid intake.
Regarding the reported food choices, significantly more
MD subjects than CD subjects changed their choice of
milk and fermented milk to milk and fermented milk with
a lower fat content, or excluded these foods totally (p =
0.003 and p = 0.038 respectively). In addition, more MD
subjects than CD subjects used olive oil and canola oil, as
well as the liquid margarine and half-fat margarine sup-
plied during the study period (p < 0.001 for all compari-
sons).
The nutrient intake during the second half of the study
was estimated by means of diet history interviews (con-
ducted with 17 individuals in each group). Two persons in
the CD group and one in the MD group were identified as
under-reporters, based on the individual Goldberg cut-off
[14] for the food intake level (FIL). In addition, one CD
subject was identified as an over-reporter. Since the results
at the group level were unchanged, whether we excluded
under- and over-reporters or not, the results of all the diet
history interviews are presented (Table 2). One exception
was however, the percentage of energy (E%) derived from
polyunsaturated fatty acids (PUFAs), which was not sig-
nificantly different between the groups when under- and
over-reporters were excluded.
According to the results from the diet history interviews,
the MD group had a lower intake of fat and saturated fatty
acids (SFAs), compared to the CD group (Table 2).
Although there was no significant difference between the
groups regarding the total intake of monounsaturated
fatty acids (MUFAs), the intake of both oleic acid (OA;
18:1n-9) and palmitoleic acid (16:1n-7) was higher in the
CD group. Regarding PUFAs, the reported intake of n-6
fatty acids did not differ significantly between the groups,
while the intake of the long-chain n-3 fatty acids was
higher in the MD group. In this group the total intake of
the n-3 fatty acids (18:3n-3, 20:5n-3 and 22:6n-3) was 3.1
g/day (of which EPA+DHA constituted 1.2 g/day), versus
2.0 g/day (EPA+DHA = 0.4 g/day) in the CD group. This
difference in turn resulted in a significantly lower ratio of
ingested n-6 to n-3 fatty acids in the MD group. Con-
versely, there was no significant difference between the
groups regarding the absolute intake (g/day), or in E%, of
α-linolenic acid (α-LNA; 18:3n-3) and linoleic acid (LA;
18:2n-6). In the MD group, the E% α-LNA was 0.80 and
the E% LA was 3.3, versus 0.62 E% α-LNA and 3.1 E% LA
acid in the CD group. However, as a consequence of the
difference between the groups regarding the total fat
intake, both α-LNA, LA and OA contributed to a higher
proportion of the fat intake in the MD group (mean intake
of α-LNA, LA and OA expressed as g/100 g total fat was
3.2, 13.3 and 37.4 in the MD group, and 1.9, 9.4 and 32.7
in the CD group, p < 0.001, p < 0.001 and p = 0.012,
respectively).
Fatty acid composition in serum phospholipids
At baseline there were no significant differences between
the groups regarding the composition of fatty acids in
serum phospholipids (Table 3). From baseline to the end
of the study the percentage of the saturated fatty acid ara-
chidic acid (20:0) increased slightly in the MD group.
Increased relative amounts were also observed in the MD
group regarding the n-3 fatty acids EPA and DHA, and for
the total percentage of n-3 fatty acids. As regards n-6 fatty
acids, there was a decrease in the relative amount of
dihomo-γ-linolenic acid (20:3n-6) and in the total per-
centage of n-6 fatty acids in the MD group. The differences
in the proportions of n-6 and n-3 fatty acids in this group,
resulted in a decrease in the n-6:n-3 ratio. In the CD group
there were no significant changes in any of the fatty acids
analyzed. When the correlation between the reported
intakes of individual fatty acids and their relative amounts
in s-phospholipids was calculated, both the relative intake
of EPA (g/100 g total fat) and the absolute intake of EPA
(g/day) were significantly correlated to the percentage of
EPA in s-phospholipids (Table 4). Also the relative and
absolute intakes of DHA were related to the percentage of
EPA in s-phospholipids. Regarding α-LNA there was a sig-
nificant correlation between the absolute intake of α-LNA
(g/day) and the level of α-LNA in s-phospholipids.
Furthermore, changes in the reported consumption fre-
quencies of fish and shellfish were positively related to
changes in EPA, DHA and the total percentage of n-3 fatty
acids in s-phospholipids (Table 4).
Differences between diet responders and diet non-
responders
When the MD group was divided into diet responders (n
= 15) and diet non-responders (n = 11), based on their
clinical improvement during the study, the diet respond-
ers had a higher reported relative intake (fatty acids
expressed in relation to the total fat intake) of EPA, docos-
apentaenoic acid (22:5, which in the food composition
database used includes both n-3 and n-6 isomers) and
DHA compared to the diet non-responders (p = 0.032, p
= 0.040 and p = 0.011 respectively). This resulted in a
lower intake ratio of n-6 to n-3 fatty acids in the group of
diet-responders. The median n-6 to n-3 ratio was 2.2 in
the diet responders and 3.0 in the diet non-responders (p
= 0.032). Also the intake of the MUFA palmitoleic acid
(16:1n-7), in relation to the total fat intake, was higher in
the diet responders (p = 0.015), while the E% of total
MUFAs was higher in the diet non-responders (p = 0.048).Nutrition & Metabolism 2005, 2:26 http://www.nutritionandmetabolism.com/content/2/1/26
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However, when the intake of total MUFAs was expressed
in relation to the total fat intake there was no significant
difference between the groups (p = 0.380).
Regarding the fatty acid composition in serum phosphol-
ipids there were some differences between the diet
responders and the diet non-responders at baseline. The
diet responders had a higher relative amount of lignoceric
acid (24:0) and lower relative amounts of arachidic acid
(20:0), vaccenic acid (18:1n-7) and α-LNA (p = 0.042, p =
0.022, p = 0.007 and p = 0.024 respectively). The change
in fatty acid composition from baseline to the end of the
study also differed between the groups. The relative
amounts of the SFAs palmitic acid (16:0) and stearic acid
(18:0), as well as the total SFAs, increased in the diet non-
responders, while these fatty acids decreased in the diet
responders (p = 0.040, p = 0.033 and p = 0.007 respec-
tively for differences between the groups). On the other
hand, the n-3 fatty acid docosapentaenoic acid (22:5n-3)
increased in the diet responders while a slight decrease
was observed in the diet non-responders (p = 0.048).
Regarding the other n-3 fatty acids in serum phospholip-
ids, no significant differences were found between the
groups.
No significant differences between the groups were
observed concerning the reported consumption of food
groups. However, from baseline to the end of the study
there was a tendency towards a greater increase in the fish
consumption (p = 0.059), as well as a greater decrease in
the consumption of dairy products with 10–15% fat (p =
0.076), in the group of diet responders compared to the
non-responders.
Discussion
Dietary intake of fat and specific fatty acids
In this study we used a questionnaire to estimate the
reported consumption of foods with relevance to the fatty
acid intake, and diet history interviews to assess the intake
of fat and specific fatty acids. In the MD group, the
changes in the reported consumption of food items were
in line with the advice given to the patients, i.e. to replace
Table 2: Comparison of average daily intake (excluding supplements) of energy, fat and specific fatty acids between the Mediterranean 
Diet (MD) group and the Control Diet (CD) group. The dietary intake is based on the diet history interviews performed between study 
weeks seven and twelve.
MD group (n = 17) CD group (n = 17) P-value*
Energy (MJ) 8.8 ± 1.6 9.8 ± 3.2 p = 0.242
Fat (g) 60.4 ± 21.9 89.3 ± 33.1 p = 0.005
Total saturated fatty acids (g) 18.3 ± 8.2 40.5 ± 18.3 p < 0.001
Total monounsaturated fatty acids (g) 25.3 ± 10.5 31.9 ± 11.1 p = 0.088
Total polyunsaturated fatty acids (g) 11.8 ± 3.9 10.6 ± 3.5 p = 0.381
Total n-6 fatty acids (g)† 7.9 ± 2.5 8.2 ± 2.7 p = 0.743
Total n-3 fatty acids (g)‡ 3.1 ± 1.3 2.0 ± 0.9 p = 0.008
Ratio n-6:n-3 2.7 ± 0.6 4.4 ± 0.9 p < 0.001
Fat (E%§) 25.0 ± 5.3 33.7 ± 5.6 p < 0.001
Total saturated fatty acids (E%) 7.5 ± 2.4 15.0 ± 3.7 p < 0.001
Total monounsaturated fatty acids (E%) 10.5 ± 2.8 12.2 ± 2.2 p = 0.067
Total polyunsaturated fatty acids (E%) 5.0 ± 1.1 4.1 ± 1.1 p = 0.028¶
Fatty acids (g):
4:0–10:0 0.77(0.32–1.59) 3.51(1.72–4.79) p < 0.001
12:0 0.44(0.28–0.93) 1.67(0.93–2.56) p < 0.001
14:0 1.81(1.07–2.90) 4.68(2.79–6.19) p < 0.001
16:0 9.46(7.29–13.29) 18.54(14.98–26.00) p < 0.001
18:0 2.80(1.99–4.34) 6.85(5.94–9.97) p < 0.001
20:0 0.14(0.10–0.19) 0.19(0.16–0.38) p = 0.016
16:1n-7 0.95(0.70–1.22) 1.25(1.05–1.84) p = 0.014
18:1n-9 20.50(14.98–28.05) 27.55(21.52–35.67) p = 0.049
18:2n-6 7.42(5.80–9.46) 7.90(5.78–9.77) p = 0.892
18:3n-3 1.79(1.23–2.36) 1.42(1.09–2.09) p = 0.454
20:4n-6 0.08(0.05–0.10) 0.08(0.04–0.13) p = 0.708
20:5n-3 0.35(0.23–0.59) 0.11(0.06–0.18) p < 0.001
22:5, n-3 and n-6 0.07(0.05–0.11) 0.02(0.01–0.05) p = 0.001
22:6n-3 0.73(0.44–1.03) 0.21(0.12–0.30) p < 0.001
Data are presented as mean ± SD for normally distributed variables and as medians (25th–75th percentiles) for variables with skew distributions. 
*The P-values refer to the difference between diet- and control group. Differences between groups were analyzed by the Students t-test for 
independent samples for normally distributed variables and by the Mann-Whitney U test for variables with skew distributions; †sum of 18:2n-6 and 
20:4n-6; ‡sum of 18:3n-3, 20:5n-3 and 22:6n-3; §E% = percent of total energy. ¶Difference between groups regarding E% polyunsaturated fatty acids 
was not significant (p = 0.101) when under- and over-reporters were excluded.Nutrition & Metabolism 2005, 2:26 http://www.nutritionandmetabolism.com/content/2/1/26
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meat, and processed meat with fish and poultry, to use
olive oil, canola oil or margarine based on canola oil, and
to choose low fat dairy products. This was also reflected in
the reported intake of fat assessed by the diet history inter-
views. For instance, choosing low fat dairy products
instead of higher fat alternatives is likely to result in a
decreased intake of both total fat and of SFAs. Thus, both
assessments of dietary intake indicated that the MD group
changed their dietary intake in the direction aimed at.
The traditional Cretan Mediterranean diet is well known
for its high content of MUFAs from olive oil. According to
a study by Cleland at al, the incorporation of EPA into
neutrophil membranes after fish-oil supplementation was
higher in healthy subjects eating a diet high in OA and low
in LA, compared to subjects on a diet high in LA [15].
Thus, when the dietary intake of OA is high in relation to
LA, this may be of advantage to the n-3 fatty acids in the
competition between n-6 and n-3 fatty acids. In this study
we also used canola oil which, similar to olive oil, is rich
in the MUFA OA. Nevertheless, there was a tendency
towards a lower intake of MUFAs in the MD group (p =
0.088). This was probably a result of the considerably
lower intake of total fat in this group, since the relative
amount of OA was still significantly higher than in the CD
group.
Among the most important characteristics of the experi-
mental diet was the amount of n-3 fatty acids and the rela-
tion between n-6 and n-3 fatty acids. The original Cretan
Mediterranean diet was rich in n-3 fatty acids from both
animal sources and plant sources [16]. In the present
study, the MD group was instructed to use canola oil and
margarine based on canola oil, which are good sources of
α-LNA. This, together with an increased intake of fish and
shellfish, resulted a significantly lower ratio of n-6:n-3
Table 3: Comparison of the fatty acid composition (per cent of total fatty acids) in serum phospholipids between the Mediterranean 
Diet (MD) group and the Control Diet (CD) group.
MD group (n = 26) CD group (n = 25) P-value*
Time (weeks after dietary shift) Time (weeks after start of study)
031 203 1 2
16:0 28.3 (23.6–31.0) 29.0 (24.6–32.2) 27.8 (25.3–31.3) 28.9 (27.2–31.7) 29.4 (27.1–32.3) 29.8 (26.6–32.1) 0.797
18:0 14.5 (13.1–15.2) 13.7 (12.2–15.3) 13.7 (12.4–15.7) 15.0 (13.2–17.1) 14.6 (13.3–16.5) 15.0 (13.3–17.0) 0.584
20:0 0.0 (0.0–0.1) 0.0 (0.0–0.2) 0.0 (0.0–0.3)† 0.0 (0.0–0.2) 0.0 (0.0–0.2) 0.0 (0.0–0.2) 0.100
24:0 1.4 (1.0–2.2) 1.4 (1.0–1.9) 1.6 (1.1–2.0) 1.4 (1.0–1.6) 1.1 (0.8–1.7) 1.3 (0.8–1.8) 0.959
Total saturated 
fatty acids
44.0 (39.1–46.8) 44.7 (37.8–48.3) 43.9 (39.6–49.4) 45.6 (41.4–49.9) 45.6 (41.1–49.1) 46.0 (42.7–49.9) 0.705
16:1n-7 0.8 (0.6–0.9) 0.7 (0.6–0.8) 0.8 (0.6–0.9) 0.7 (0.6–1.1) 0.8 (0.6–0.9) 0.8 (0.6–1.0) 0.339
18:1n-7 1.7 (1.3–1.8) 2.0 (1.4–2.2) 1.8 (1.6–2.0) 1.7 (1.3–1.9) 1.7 (1.5–2.1) 1.8 (1.5–2.0) 0.557
18:1n-9 9.9 (8.2–10.9) 9.7 (8.3–11.2) 9.4 (7.3–10.6) 10.2 (8.3–11.1) 10.6 (8.9–11.5) 10.9 (8.3–11.5) 0.087
22:1n-11 0.6 (0.2–1.6) 0.6 (0.2–1.5) 0.8 (0.8–1.8) 0.6 (0.0–1.3) 0.3 (0.0–1.0) 0.6 (0.0–1.1) 0.356
Total 
monounsaturated 
fatty acids
13.1 (11.4–13.8) 12.8 (11.2–14.6) 12.6 (11.3–13.8) 13.3 (11.8–14.4) 13.6 (11.6–14.7) 13.9 (11.4–15.0) 0.207
18:2n-6 16.7 (11.5–19.9) 16.5 (10.7–18.6) 14.4 (11.0–16.9) 16.0 (12.5–19.2) 16.7 (12.8–18.1) 17.0 (13.5–19.5) 0.044
20:2n-6 0.4 (0.2–0.7) 0.3 (0.2–0.5) 0.4 (0.2–0.6) 0.3 (0.2–0.5) 0.3 (0.2–0.5) 0.4 (0.3–0.6) 0.458
20:3n-6 2.6 (1.8–3.2) 2.5 (1.7–3.0) 2.2 (1.6–2.6)‡ 2.1 (1.5–3.1) 2.2 (1.7–2.8) 2.4 (1.8–3.1) 0.003
20:4n-6 6.9 (5.0–7.7) 6.8 (4.8–8.2) 6.6 (4.1–8.0) 5.9 (4.1–9.8) 6.6 (4.2–8.5) 6.5 (4.8–8.7) 0.144
Total n-6 fatty 
acids
25.2 (18.9–30.7) 26.8 (17.5–30.0) 23.8 (17.6–28.3)† 24.4 (18.4–32.2) 25.1 (19.3–29.9) 25.2 (21.5–30.5) 0.008
18:3n-3 0.3 (0.0–0.4) 0.2 (0.0–0.4) 0.4 (0.0–0.4) 0.3 (0.2–0.4) 0.3 (0.1–0.5) 0.3 (0.0–0.5) 0.395
20:5n-3 1.4 (1.1–1.8) 1.8 (1.1–2.8) 2.1 (1.4–3.3)§ 1.1 (1.0–1.5) 1.1 (1.0–1.7) 1.1 (0.9–1.4) <0.001
22:5n-3 0.7 (0.2–1.7) 0.6 (0.2–1.4) 0.8 (0.2–1.7) 0.5 (0.2–1.3) 0.6 (0.2–1.0) 0.6 (0.3–1.0) 0.395
22:6n-3 3.9 (2.2–4.8) 4.2 (3.1–6.6) 5.0 (2.5–7.2)§ 3.0 (1.5–4.3) 3.5 (1.7–4.2) 3.0 (2.2–4.5) <0.001
Total n-3 fatty 
acids
6.1 (5.2–7.4) 7.3 (5.3–10.0) 8.6 (6.0–11.7)§ 5.2 (4.3–7.0) 4.9 (3.7–6.4) 5.2 (3.8–7.0) 0.001
n-6:n-3 ratio 4.2 (3.0–5.6) 3.1 (2.7–3.7) 2.5 (2.1–3.5)‡ 4.6 (3.6–5.6) 4.4 (3.4–5.6) 4.9 (4.1–5.6) 0.002
Total 
polyunsaturated 
fatty acids
32.7 (25.9–38.4) 33.5 (24.4–40.1) 32.4 (22.7–39.0) 29.3 (22.3–37.5) 31.0 (24.0–36.6) 30.9 (25.7–37.4) 0.072
Data are presented as medians (25th–75th percentiles). *The p-values refer to differences between the MD- and the CD group concerning the 
change from baseline to week 12. Differences between the groups were analyzed with the Mann-Whitney U test. Statistically significant change from 
baseline to week 12: †p < 0.05, ‡p < 0.01, §p < 0.001. Within-group differences in week 12 compared to baseline were evaluated by the Wilcoxon 
signed ranks test.Nutrition & Metabolism 2005, 2:26 http://www.nutritionandmetabolism.com/content/2/1/26
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fatty acids in the MD group (2.7 versus 4.4). The n-6:n-3
ratio has been reported to be 1–2 in the traditional diet of
Greece, while the ratio in many Western countries is
around 15–17 [17]. However, in the Swedish nationwide
dietary survey "Riksmaten 1997–98" [18], where the pat-
terns of food and nutrient intake in Sweden were studied
on a nationwide basis, the ratio n-6:n-3 was reported to be
around 5. This is not far from the ratio in our CD group,
while the MD group obtained a ratio closer to that of the
traditional Greek diet. However, it is important to remem-
ber, that when data from different countries and different
studies are compared, different fatty acids may have been
used to calculate these ratios.
A modified Cretan Mediterranean diet, similar to our
experimental diet, has been tested by de Lorgeril et al
[19,20], in a study on secondary prevention of coronary
heart disease. In that study the aim was to reduce the
intake of LA to 4 E% and the intake of α-LNA was to
exceed 0.6 E%. After eight weeks the experimental group
in their study had an LA intake of 3.6 E% and an α-LNA
intake of 0.76 E%. In the present study, the E% of LA was
even lower and the E% of α-LNA was almost the same in
the MD group as in the study by de Lorgeril et al. How-
ever, the intake of LA and α-LNA in our CD group was not
very different from the MD group. This may be explained
by the relatively high use of canola oil and margarine
based on canola oil in Sweden. Although we encouraged
our MD group to increase the intake of these α-LNA
sources, these foods are also important sources of n-3 fatty
acids in the Swedish population in general [18]. Thus,
regarding essential fatty acids, even the intake of the CD
group was close to that of the experimental group in the
study by de Lorgeril et al [20].
In the present study, the reported total intake of n-3 fatty
acids in the MD group was 3.1 g/day and of these 1.2 g
were EPA + DHA. Most studies of dietary supplementa-
tion with fish oil have used between 1 and 7.1 g EPA +
DHA per day [2]. On the basis of these studies, a daily
intake of 3–6 g long-chain n-3 fatty acids (usually EPA +
DHA) has been recommended in order to improve RA
symptoms [5,21]. Hence, although the MD group
reported an increased consumption of fish, the intake of
long chain n-3 PUFAs only reached the lower range of the
amounts used in studies of fish oil supplementation.
However, in these studies n-3 fatty acids are usually added
to the diet, regardless of the intake of other fatty acids. In
a few supplementation studies the amount of competitor
n-6 fatty acids has been considered as well [3,22,23].
Volker et al [3] investigated the effect of fish oil supple-
mentation (40 mg/kg body weight/day) in RA subjects
with a background diet of <10 g n-6 fatty acids. After 15
weeks, the experimental group achieved substantial incor-
poration of EPA in plasma and monocyte phospholipids,
and significant improvements in six of nine outcome
measures. Furthermore, in a study by Adam et al [22] the
effect of fish oil supplementation (30 mg/kg body weight/
day) in two groups on different diets was studied. One
group were on a diet low in arachidonic acid (AA; 20:4n-
6; less than 90 mg/day) and the other group ate a normal
western diet. Patients from both groups were randomized
to receive either fish oil capsules or placebo capsules for
three months, in a double-blind, crossover manner. The
results of the study showed that patients on the AA-low
diet improved more than the other group regarding tender
and swollen joints. As the authors conclude, this indicates
that the ratio of AA:EPA is decisive for the clinical effec-
tiveness of fish oil supplementation. In the present study
both groups reported a daily intake of less than 10 g of n-
6 fatty acids, and less than 90 mg AA. Based on the studies
mentioned above, the low background intake of n-6 fatty
acids may have amplified the effect of the Mediterranean
diet.
Fatty acid composition in serum phospholipids
The dietary intake of fat is often difficult to assess by
means of dietary assessment methods. Therefore, there is
Table 4: Spearman's correlation coefficients between the reported intake of fatty acids or foods and fatty acids in serum 
phospholipids.
Fatty acids in s-phospholipids
Dietary fatty acids/foods EPA DHA α-LNA total n-3
EPA g/day 0.58* 0.24 0.04 0.43†
EPA g/100 g total fat 0.58* 0.32 0.04 0.49*
DHA g/day 0.60* 0.19 -0.05 0.40†
DHA g/100 g total fat 0.57* 0.26 -0.09 0.45*
α-LNA g/day 0.13 -0.09 0.38† 0.03
α-LNA g/100 g total fat 0.24 0.11 0.29 0.20
Change in fish intake‡ 0.48* 0.46* 0.14 0.51*
Change in shellfish intake‡ 0.33† 0.48* 0.03 0.34†
*p < 0.01; †p < 0.05; ‡change from baseline to week 12 in relation to change in percentage of fatty acids in s-phospholipids.Nutrition & Metabolism 2005, 2:26 http://www.nutritionandmetabolism.com/content/2/1/26
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a need for objective markers of fatty acid intake to be used
as a complement to dietary assessment methods [24,25].
In the present study, we measured fatty acids in serum
phospholipids, which are influenced by the dietary intake
of the past few days [26]. The changes we found regarding
the fatty acid profile were in agreement with the reported
nutrient intake, i.e. an increase in the relative amount of
n-3 fatty acids. We also observed a decrease in n-6 fatty
acids in serum phospholipids. However, since an
increased relative amount of one fatty acid cause a
decrease in the percentage of another, this is not necessar-
ily a consequence of a decreased intake of n-6 fatty acids.
Somewhat surprisingly, the saturated fatty acid arachidic
acid (20:0) increased marginally, but significantly, in the
MD group. One possible reason for this could be an
increased consumption of canola oil. Although the
amount of arachidic acid is low in canola oil, this oil con-
tains more arachidic acid than other oil, margarine or but-
ter.
The use of fatty acid patterns in serum phospholipids as
biomarkers of the dietary intake is, limited by the fact that
not only diet affects the levels of fatty acids in biological
specimens [24]. For instance, most fatty acids can be syn-
thesized by humans and, within the body, fatty acids can
also be converted to other fatty acids by means of desatu-
ration and elongation. Furthermore, the pattern of plasma
fatty acids in phospholipids has been reported to be
altered in RA patients compared to healthy subjects [27].
In this study, the strongest correlation between the intake
of fatty acids and the corresponding biomarkers, was
observed regarding EPA (rs = 0.58 for both absolute and
relative intakes). Similar, as well as both stronger and
weaker correlations have been reported by others, possi-
bly due to variations in the quality of the dietary data [28-
30]. In other studies the percentage of DHA in phosphol-
ipids has been correlated to the intake of this fatty acid
[28,29], while in the present study, the intake of DHA was
only correlated to the percentage of EPA in phospholip-
ids. The reason for this is probably that the dietary sources
of EPA and DHA are the same. Also a significant correla-
tion between α-LNA in serum phospholipds and the abso-
lute intake of this fatty acid (rs = 0.38) was found in the
present study. This result is partly in line with a study by
Sasaki et al [31], while others have reported only weak
correlation regarding α-LNA [29,30].
Sometimes, the relative fatty acid levels reflect the intake
of specific foods, especially when the food item is the
major source of the fatty acid in question. In this study
changes in the reported consumption of fish and shellfish
were related to changes in the percentage of both EPA,
DHA and total n-3 fatty acids, with Spearman's correla-
tion ranging from 0.46 to 0.51 for fish and from 0.33 to
0.48 for shellfish. Regarding fish intake, this is in agree-
ment with other studies [28,32,33]. The correlation
between shellfish intake and long-chain n-3 fatty acids
may also be related to the consumption of fish. Although
the reported intake of shellfish increased significantly in
the MD group, the level of shellfish consumption was not
very high in this study. Thus, compared to the intake of
fish, shellfish was probably not a major source of n-3 fatty
acids. Furthermore, there was a significant correlation
between the change in fish intake and the change in shell-
fish intake (data not shown), indicating that the individ-
uals reporting an increased intake of shellfish are likely to
be the same individuals as those with an increased fish
intake.
Can the altered intake of fatty acids explain the beneficial 
effects on RA disease activity?
To analyse the possible connection between the altered
intake of fatty acids in the MD group and the improve-
ment regarding disease activity, we divided the MD group
into diet responders and diet non-responders, based on
the individual change in disease activity during the study.
It is important to remember that only 15 (diet responders)
and 11 (diet non-responders) patients were compared in
this analysis. Hence, the power to detect differences
between diet responders and diet non-responders was
fairly low. Still, when these two groups were compared
differences in both the reported intake of fatty acids and
the fatty acid composition in serum phospholipids were
found. Overall, the results point towards a more favoura-
ble fatty acid intake in the group of diet responders, at
least regarding PUFAs, which in turn suggests a better
compliance to the experimental diet in this group. Thus,
the differences found between diet responders and diet
non-responders indicate that the fatty acid intake contrib-
uted to the positive effect of this diet on RA disease activ-
ity.
Conclusion
In conclusion, the changes in the reported consumption
of food items in the MD group were in line with the advice
given during the study. As a result, the total fat intake was
lower in the MD group compared to the CD group, and in
the MD group a lower percentage of the energy intake was
derived from SFAs. The MD group also had a lower intake
ratio of n-6:n-3 fatty acids. A corresponding change in the
relation between n-6 and n-3 fatty acids was observed in
s-phospholipids. Furthermore, the MD patients who were
characterised as diet responders, had a higher reported
intake of long chain n-3 fatty acids and a lower ratio of n-
6 to n-3 fatty acids compared to the diet non-responders.
Also the fatty acid profile in serum phospholipids differed
in part between the diet responders and the diet non-
responders. These findings point towards a better compli-
ance to the experimental diet in the group of diet respond-
ers.Nutrition & Metabolism 2005, 2:26 http://www.nutritionandmetabolism.com/content/2/1/26
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Altogether, the changes in the fatty acid profile indicated
by three methods, a questionnaire, diet history interviews
and fatty acids in s-phospholipids may, at least in part,
explain the beneficial effects on the clinical measurements
demonstrated earlier [1]. Thus, the results of this study
support previous studies indicating the importance of the
fatty acid intake in patients with RA.
Methods
Patients, study design and the experimental diet
The study was a randomised, parallel, dietary intervention
study over three months. In total, 56 patients with RA
were included in the study. Of these, 26 MD subjects (21
women and 5 men, mean age 58 years) and 25 CD sub-
jects (20 women and 5 men, mean age 59 years) com-
pleted the study. The patients, study design and the
dietary intervention have been described in detail else-
where [1,34]. In brief, the patients were randomized to
either a modified Cretan Mediterranean diet group or a
control diet group, by means of block randomization
stratified for sex. At baseline the two groups were equal
except for the disease duration and the body mass index
(BMI). The MD group had a significantly higher BMI and
a longer disease duration compared to the CD group (p =
0.024 and 0.047, respectively).
The experimental diet used in the present study was based
on the Cretan Mediterranean diet previously tested by de
Lorgeril et al, in a secondary prevention study of coronary
heart disease [19]. However, some modifications of the
diet were done in order to suit Swedish food habits. We
instructed our MD group to eat a large amount of vegeta-
bles, fruit, pulses, cereals, fish (particularly fish with a
high content of ω-3 fatty acids) and nuts and seeds with a
high content of α-LNA. The intake of meat (such as pork,
beef, lamb or mutton) and processed meat (including
cured meat, sausage, pâté or the like) were to be replaced
by poultry, fish or vegetarian dishes. Both olive oil and
canola oil were used in salad dressings and for food prep-
aration. The MD group was also informed to use two types
of margarine based on canola oil: a liquid margarine
(80% fat) for food preparation and half-fat margarine
(40% fat) to use on bread. In addition, the MD group was
advised to replace high fat dairy products with low fat
products. In the present study, no recommendations were
given regarding alcohol consumption. To compensate for
the antioxidants in wine, we advised the MD group to
drink green or black tea.
To promote good compliance with the Mediterranean diet
some food items were supplied free to the MD group,
namely: frozen vegetables, tea, olive oil, canola oil and the
liquid and half-fat margarine based on canola oil. Olive
oil and canola oil, were supplied by Karlshamns AB, veg-
etables by Nestlé Sweden AB and margarine and tea by
Van den Bergh Foods AB.
The CD subjects were instructed to adhere to their ordi-
nary diet. If the subjects of the study used any dietary sup-
plementation (e.g. fish oils, vitamins, minerals, etc.) prior
to the study this was recorded. All such supplementation
had to be kept unchanged during the study.
Dietary assessments
To assess the dietary intake both a self-administered ques-
tionnaire and diet history interviews were used. The ques-
tionnaire was completed by the patients of both groups at
baseline, in week three and twelve. This questionnaire
included both open and closed questions, mainly con-
cerning food choices, and it was designed to investigate
compliance with the Mediterranean diet. Regarding ques-
tions on frequencies of food intake, the subjects should
state their average intake of various food items by marking
one of six alternatives ranging from "rarely or never" to
"two or more times per day". To enable comparisons of
the consumption between the two groups, as well as con-
sumption at different points in time, the food frequencies
were converted to average consumption per month. For
example, if a consumption of 3–5 times per week was
marked this would be converted to 16 times per month.
Diet history interviews, covering the dietary intake during
the past month, were carried out to obtain more detailed
data on the energy and nutrient intake during the inter-
vention period. The interviews were performed between
study weeks seven and twelve and were conducted with 34
patients from both the MD group and the CD group (15
women and 2 men from each group). The only selection
criterion for taking part in the diet history interviews was
that the subjects were included in the study on February
15th 1999, or later. Fore more details regarding the ques-
tionnaire and the diet history interviews see reference 34.
The nutritional analysis package MATs 4_03e was used to
calculate the estimated intake of energy and nutrients
based on the diet history interviews. This program is based
on the Swedish National Food Administration's food
composition database, PC-kost (version 2_97). If com-
posite food items and supplements not listed in the data-
base were reported, the nutrient content was entered
manually. The energy and nutrient intake was calculated
both including and excluding dietary supplements. Still,
when dietary supplements were included, the total intake
of n-3 fatty acids increased marginally in the MD group
and not at all in the CD group. Therefore, only the dietary
intake without supplements will be presented. However,
when the correlation between the reported dietary intake
of fatty acids and their relative content in s-phospholipidsNutrition & Metabolism 2005, 2:26 http://www.nutritionandmetabolism.com/content/2/1/26
Page 9 of 11
(page number not for citation purposes)
were analyzed, the results from the diet history interviews
including supplements were used.
Validation of the diet history interviews
A validation of the diet history interviews by means of the
doubly labelled water method (performed for nine sub-
jects) and biological markers of the intake of protein,
sodium and potassium has been presented elsewhere
[35]. To identify under- and over-reporters we used the
individual Goldberg cut-offs for the FILs [14]. These cut-
offs are based on the physical activity level for each subject
assessed by a three-day activity registration, which has
been described earlier [35]. The FIL is the individuals
reported energy intake divided by the estimated basal
metabolic rate. The basal metabolic rate was estimated
based on body weight, age group and sex, according to
standard equations [36].
Categorization of diet responders and diet non-responders
In this intervention study the disease activity was assessed
by means of a combined index called disease activity score
from 28 joints (DAS28) [37]. The patients in the MD
group who had a moderate or better clinical improvement
from baseline to the end of the study, which is defined as
a decrease of >0.6 in DAS28, were categorized as diet
responders and the remaining MD patients as diet non-
responders.
Determination of the composition of fatty acids in serum 
phospholipids
Sampling
Blood samples for the analysis of fatty acids in serum
phospholipids were taken at baseline and in weeks three
and twelve. After a one-night fast, samples were collected
in tubes without additives. The blood was cooled in ice
water for 30 min before centrifugation at 1500 g for 15
min at +4°C. The serum was separated and stored at -
70°C until analysis.
Folch extraction
Serum (1 ml) was extracted using methanol (2 ml) and
chloroform (4 ml). Potassium chloride, 0,88%; (2 ml
with the water content of the sample excluded) was added
and the mixture was shaken thoroughly for 30 seconds
before being allowed to settle. The aqueous layer was
removed, one fourth of the volume of the organic phase
of methanol-saline (1:1, v/v) was added and the washing
procedure was repeated. The bottom layer containing the
purified lipids was collected and the solvent was evapo-
rated in a gentle stream of nitrogen at +30°C [38].
Separation of lipid classes using thin layer chromatography (TLC)
The purified lipids were solved in 40 µl chloroform con-
taining 0,05% (v:v) of antioxidant butylated hydroxytolu-
ene (BHT, 10% in ethanol (w:v)) and separated on silica
gel plates 60, F254  (MERCK) by TLC, using petrole-
umether: diethyl ether: acetic acid (81:18:1). The different
lipid classes were visualized using UV-light at 254 nm. The
standards used were L-α-Phosphatidylcholine and L-α-
Phosphatidylethanolamine, Larodan Fine Chemicals. The
phospholipid spots were transferred into screw-capped
glass tubes for preparation of fatty acid methyl esters [39].
Transesterification using sodium methoxide
The silica gel containing the lipids was dissolved in
sodium-dried diethyl ether (0,5 ml) and methyl acetate
(20 µl). Sodium methoxide, 0,5 M, in dry methanol (20
µl) was added. After 15 minutes at room temperature the
reaction was stopped by the addition of acetic acid (2 µl).
The solvent was evaporated in a gentle stream of nitrogen
at +30°C. Iso-hexane with BHT (0,05%; 1 ml) was added
and the mixture was centrifuged at 1500 g for 2 minutes.
The supernatant layer was removed using a Pasteur pipette
into a sample tube [40].
GC analysis
The composition of the fatty acids was determined using
gas chromatography. Of the purified methylated sample 1
µl was injected into a HP 5890 series II gas chromatograph
suited with a FID and an HP-FFAP capillary column (30 m
× 0,25 mm × 0,25 µm). The He carrier gas flow was 13 ml/
min. The detector temperature was 260°C. The injector
split 1:50 at 220°C. A temperature programme was used
with an initial temperature of 160°C held for 5 minutes,
raised from 160 to 220°C at a rate of 2°C/min and 220°C
held for 30 minutes.
The fatty acid methyl esters were identified by comparison
with the retention times of the standards: GLC-68D and
GLC-68A, Nu-Chek-Prep and Qualimix Fish 89 – 5540,
Larodan Fine Chemicals.
The individual fatty acids were expressed as the percentage
of total fatty acids (relative amount). The relative amounts
were quantified by integrating the area under the peak and
dividing the results by the total area of all fatty acids.
Statistical methods
The statistical analyses were performed using SPSS for
Windows version 11.0.1. The differences in fat intake
between groups were analyzed using the Student's t-test
for independent samples, when the variables were nor-
mally distributed. For fatty acids with skewed distribu-
tions the Mann-Whitney U test was used. As regards the
reported consumption of food items and the composition
of fatty acids in serum phospholipids, the Mann-Whitney
U-test was performed to test differences between groups at
baseline. For these variables, within group differences
from baseline to week 12 were evaluated by means of the
Wilcoxon signed ranks test.Nutrition & Metabolism 2005, 2:26 http://www.nutritionandmetabolism.com/content/2/1/26
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The Spearman's rank correlation was used to evaluate the
association between the reported dietary intake of fatty
acids (assessed by diet history interviews including sup-
plements) and their relative content in s-phospholipids.
When calculating the correlation, the mean value of the
results from week six and twelve were used regarding fatty
acids in s-phospholipids, since the diet history interviews
were performed between study weeks seven and twelve.
Spearman's rank correlation was also used to evaluate the
association between the reported consumption of fish
(estimated by means of the questionnaire) and the long
chain n-3 fatty acids in s-phospholipids. For these assess-
ments the change from baseline to week 12 was used.
All results were considered statistically significant at a
two-tailed p-value of <0.05.
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